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Review Paper 
The first words which come to our mind about 
cancer stem cells (CSCs) are “What are cancer stem 
cells?”. Recent studies have suggested that CSCs are 
immortal tumor-initiating cells that can self-renew 
with pluripotent capacity. There are several common 
characteristics between somatic stem cells and 
cancer stem cells such as they could self-renew, are 
highly regulated, differentiated, and resistant to 
apoptosis, and have long lifespan, but some 
differences have been observed such as producing 
tumor metastasize to distant sites through CSCs 
while somatic stem cells produces mature tissue 
through migration to distant tissues (1, 2). thought to 
be the basis for tumor initiation, metastasis, 
development and recurrence (3). Besides, cancer 
stem cells have several features including (4-6): 
References 
 
1. Spillane JB, Henderson MA. Cancer stem cells: a review. ANZ journal of surgery. 2007;77(6):464-8. 
2. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells—perspectives on current 
status and future directions: AACR Workshop on cancer stem cells. Cancer research. 2006;66(19):9339-44. 
3. Chen K, Huang Y-h, Chen J-l. Understanding and targeting cancer stem cells: therapeutic implications and challenges. 
Acta Pharmacologica Sinica. 2013;34(6):732-40. 
4. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007;23:675-
99. 
5. Rivera C, Rivera S, Loriot Y, Vozenin M-C, Deutsch E. Lung cancer stem cell: new insights on experimental models 
and preclinical data. Journal of oncology. 2010;2011. 
Over the past several decades, accelerating scientific and technological advances 
have enabled researchers to make a great quantity of knowledge in the field of 
cancer biology. Numerous genes, mutant alleles, proteins, and signalling networks 
involved in the initiation and progression of cancer have been identified and some 
of the mechanisms deliberating resistance to therapy. Because of the limited 
efficacy of presently available treatment modalities, the cancer results to death and 
distress. One of the most important and complicated topics about the cancer is 
cancer stem cells (CSCs). The CSCs are immortal tumor-initiating cells that share 
some characteristics with normal stem/progenitor cells. Some of their important 
characteristics are self-renewal and multilineage differentiation. Since CSCs have 
potential resistance to chemotherapeutic agents as well as radiation therapy, it 
makes a serious challenge for current cancer treatments. There are various 
strategies for eradicating CSCs. Targeting of CSCs usually occurs by 
pharmacological targeting, immunotherapy and genetic targeting (miRNA, 
oncolytic virus). More recently, nanomedicine considerably extends the anticancer 
drugs, treatment strategies, and targeting CSCs. In this field, all currently available 
strategies could be divided into three major sections: Drug delivery targeting 
CSCs (nanocarriers such as nanoparticles (NPs), liposomes, micelles, nanotubes 
and nanogels), targeting genes of drug resistance and destruction the CSCs niches. 
In this review, we discussed some characteristics of CSCs and their therapeutic 
strategies. 
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1) Self-renewal 
2) Multipotent differentiation 
3) Tumorigenic potential 
4) Expression of stem cell markers 
5) Enhanced invasiveness 
6) Proliferation as tumor spheres 
7) Radio resistance 
8) Chemo resistance 
9) Resistance to hypoxia 
10) Resistance to apoptosis 
11) Quiescence 
12) Expression of Sox2, Nanog, and Oct4 in CSCs 
Several pathways are involved in CSC self-renewal 
that is shown in table 1.  
CSCs have several biomarkers which are used in 
the isolation and characterization of them shown in 
table 2. 
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Signalling Pathways                Type of Cancer 
WNT CML, AML, Breast Cancer 
Hedgehog 
Breast Cancer, Pancreatic 
Cancer, CML, Glioblastoma, 
Notch 
Colon Cancer, Breast Cancer, 
Glioblastoma 
BMI1 
Murine Acute Myeloid 
Leukemia, Breast Cancer, 
Head and Neck Squamous 
Cell Cancer, Glioblastoma, 
Acute Myeloid Leukemia 
PTEN Murine Leukemia, Breast 
BMP  Glioblastoma 
TGF-B             Glioblastoma 
Abbreviation: BMP, Bone Morphogenic Protein. 
Table 1. CSC and self renewal (7) 
 Tumor Type Marker(s) Used to Enrich 
for CSCs  
Acute Myeloid Leukemia CD34+ CD38- 
Breast CD44+ CD24- ALDH1+ 
Brain CD133+ 
Prostate CD44+ CD133+ α2β1
high 
Head and neck CD44+ 
Colon 
CD133+ ALDH1 + CD44+ 
highEpCAM 
Pancreas ESA + CD44+ CD133+ CD24+ 
Mesenchymal Side Population 
Lung CD133+ 
Liver CD90+ 
Melanoma ABCB5+ 
Ovarian  CD133  
Table 2. CSC biomarkers (7-9) 
ATP-binding Cassette 
ATP-binding cassette (ABC) transporters are 
membrane transporters that can pump different 
dissimilar and structurally unrelated small  
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molecules (such as dyes and cytotoxic drugs) out of 
cells through ATP hydrolysis. Cancer stem cells and 
normal stem cells appear to express high levels of 
ABC transporters. This phenomenon could 
contribute to multi-drug resistance because various 
anti–tumor drugs can be pumped out, thereby 
resulting in low intracellular drug concentrations 
(10). 
There are many mechanisms causing resistance of 
CSC including: 
1. Modulation of Cell Cycle Kinetics 
2. Habitation in Hypoxic Niches 
3. Proficient Mechanisms of DNA Repair 
4. Relative Resistance to Oxidative or DNA 
Damage 
5. Intrinsic Expression of Anti-Apoptotic Molecules 
6. High Expression of Multidrug-Resistance-Type 
Membrane Transporters 
7. Chemoresistance of Cancer Stem Cells Due to 
Quiescence 
8. Chemoresistance of Cancer Stem Cells Due to 
Aldehyde Dehydrogenase Activity (10, 11) 
Different strategies that targets cancer stem cells 
including: 
1. Suppressing proliferation of CSCs 
2. Destroying CSC niche 
3. Inducing the differentiation of CSCs 
4. Inducing apoptosis of CSCs 
5. Increasing sensitivity of CSCs to radiotherapy 
and chemotherapy (12). 
How therapeutic strategies target cancer stem cells? 
There are several mechanisms: 
 
Pharmacological Targeting 
Small molecule inhibitors have shown promising 
results when are used alone or in combination to 
target slow growing chemo- and radio-resistant 
CSCs. Several strategies have been employed 
including targeting signalling pathways that affect 
chemo- and radio-resistance to CSCs, thus 
increasing their susceptibility to conventional 
therapies (13). 
 
Immunotherapy 
Cancer stem cells have been associated with 
immunosuppressive properties (14), which are likely 
a critical part of the mechanism which provides the 
cells with tumor-promoting and immunomodulatory 
characteristics. Understanding the many different 
immunosuppressive pathways in CSCs allows for a 
more effective design of therapeutic elimination 
strategies (13). 
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Conclusion 
The identification of CSCs and the recent knowledge about their ability to resist common radio- and 
chemotherapy have urged a number of new targeting strategies to attack this rare but extremely important 
tumor subpopulation in order to eradicate cancer. It is necessary to mention focusing on CSCs’ markers and 
related signaling pathways, have been also useful tools to find appropriate therapies. However, the CSC 
paradigm has provided exciting novel venues to improve cancer treatment by lowering recurrence and 
metastasis, which are considered to be the main cause of most cancer mortalities. 
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